Bayer subsidiary Vividion Therapeutics and precision oncology company Tavros Therapeutics entered into a five-year collaboration agreement, valued at up to $930 million, to discover and develop four novel oncology targets.
https://www.pharmalive.com/wp-content/uploads/2022/08/BioSpaceBayer8-29-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-12 09:27:262022-10-12 12:33:42Bayer’s Vividion bets up to $930M for Tavros oncology partnership